Empowering Early Intervention: Navigating Treatments for Delaying T1D Progression, Insights from UC San Diego Health : Episode 4

Navigating T1D Risk Screening: Identifying Ideal Candidates, Understanding Autoantibodies, and Determining Timing for Rescreening

June 11, 2024

By Jennifer D. Goldman, RPh, PharmD, CDCES, BC-ADM, FCCP
Steven Edelman, MD

Opinion

Video

Following a couple of audience polling questions, Andrea Stallings, PA and her UCSD colleagues, comment on identifying suitable candidates for T1D screening, understanding autoantibodies involved in this condition, and determining when to rescreen those at risk for disease progression.

EP: 1.Insights into the Burden of T1D: Genetic Links and Familial Considerations from UCSD Practitioners

EP: 2.The Vital Importance of Understanding and Addressing Training Gaps in Endocrinology Surrounding T1D Stages

EP: 3.The Crucial Impact of Early Intervention in Preventing T1D Stage Progression

Now Viewing

EP: 4.Navigating T1D Risk Screening: Identifying Ideal Candidates, Understanding Autoantibodies, and Determining Timing for Rescreening

EP: 5.Understanding Autoantibody Screening Tests: Methods, Interpretation, and Analysis Practicalities

EP: 6.Exploring the First FDA-Approved Treatment to Delay T1D Onset: Mechanism of Action and Treatment Impact

EP: 7.Exploring the TN-10 Teplizumab Clinical Trial: Patient Demographics and Efficacy Insights

EP: 8.Teplizumab Infusion Protocol: Clinical Processes and Strategies for Infusion Access Enhancement

EP: 9.Key Insights and Practical Tips: Wisdom from UCSD Practitioners for Effective T1D Management

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!